vs

Side-by-side financial comparison of ARROW FINANCIAL CORP (AROW) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $35.0M, roughly 1.0× ARROW FINANCIAL CORP). ARROW FINANCIAL CORP runs the higher net margin — 24.6% vs -304.2%, a 328.8% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 7.1%). ARROW FINANCIAL CORP produced more free cash flow last quarter ($7.5M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 6.4%).

Flagstar Bank, N.A. (FLG), is an American regional financial services holding company headquartered in Hicksville, New York. In 2023, the bank operated 395 branches However, they rebranded all of these under the Flagstar name on February 21, 2024.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

AROW vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.0× larger
RXRX
$35.5M
$35.0M
AROW
Growing faster (revenue YoY)
RXRX
RXRX
+674.6% gap
RXRX
681.7%
7.1%
AROW
Higher net margin
AROW
AROW
328.8% more per $
AROW
24.6%
-304.2%
RXRX
More free cash flow
AROW
AROW
$54.8M more FCF
AROW
$7.5M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
6.4%
AROW

Income Statement — Q2 FY2024 vs Q4 FY2025

Metric
AROW
AROW
RXRX
RXRX
Revenue
$35.0M
$35.5M
Net Profit
$8.6M
$-108.1M
Gross Margin
59.8%
Operating Margin
-304.8%
Net Margin
24.6%
-304.2%
Revenue YoY
7.1%
681.7%
Net Profit YoY
42.3%
39.6%
EPS (diluted)
$0.52
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AROW
AROW
RXRX
RXRX
Q4 25
$35.5M
Q3 25
$5.2M
Q2 25
$19.2M
Q1 25
$14.7M
Q4 24
$4.5M
Q3 24
$26.1M
Q2 24
$35.0M
$14.4M
Q1 24
$34.3M
$13.8M
Net Profit
AROW
AROW
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$-162.3M
Q2 25
$-171.9M
Q1 25
$-202.5M
Q4 24
$-178.9M
Q3 24
$-95.8M
Q2 24
$8.6M
$-97.5M
Q1 24
$7.7M
$-91.4M
Gross Margin
AROW
AROW
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
AROW
AROW
RXRX
RXRX
Q4 25
-304.8%
Q3 25
-3327.6%
Q2 25
-916.8%
Q1 25
-1297.9%
Q4 24
-4042.4%
Q3 24
-377.1%
Q2 24
-697.4%
Q1 24
-698.4%
Net Margin
AROW
AROW
RXRX
RXRX
Q4 25
-304.2%
Q3 25
-3135.3%
Q2 25
-894.2%
Q1 25
-1373.3%
Q4 24
-3935.5%
Q3 24
-367.5%
Q2 24
24.6%
-676.6%
Q1 24
22.3%
-662.4%
EPS (diluted)
AROW
AROW
RXRX
RXRX
Q4 25
$-0.17
Q3 25
$-0.36
Q2 25
$-0.41
Q1 25
$-0.50
Q4 24
$-0.56
Q3 24
$-0.34
Q2 24
$0.52
$-0.40
Q1 24
$0.45
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AROW
AROW
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$383.0M
$1.1B
Total Assets
$4.2B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AROW
AROW
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$296.3M
Total Debt
AROW
AROW
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
AROW
AROW
RXRX
RXRX
Q4 25
$1.1B
Q3 25
$1.0B
Q2 25
$919.1M
Q1 25
$933.9M
Q4 24
$1.0B
Q3 24
$524.6M
Q2 24
$383.0M
$584.4M
Q1 24
$378.0M
$401.2M
Total Assets
AROW
AROW
RXRX
RXRX
Q4 25
$1.5B
Q3 25
$1.4B
Q2 25
$1.3B
Q1 25
$1.3B
Q4 24
$1.4B
Q3 24
$726.5M
Q2 24
$4.2B
$775.9M
Q1 24
$4.3B
$557.8M
Debt / Equity
AROW
AROW
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AROW
AROW
RXRX
RXRX
Operating Cash FlowLast quarter
$9.1M
$-46.1M
Free Cash FlowOCF − Capex
$7.5M
$-47.3M
FCF MarginFCF / Revenue
21.5%
-133.1%
Capex IntensityCapex / Revenue
4.5%
3.5%
Cash ConversionOCF / Net Profit
1.06×
TTM Free Cash FlowTrailing 4 quarters
$9.6M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AROW
AROW
RXRX
RXRX
Q4 25
$-46.1M
Q3 25
$-117.4M
Q2 25
$-76.4M
Q1 25
$-132.0M
Q4 24
$-115.4M
Q3 24
$-59.2M
Q2 24
$9.1M
$-82.2M
Q1 24
$10.3M
$-102.3M
Free Cash Flow
AROW
AROW
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$7.5M
$-83.4M
Q1 24
$9.2M
$-109.0M
FCF Margin
AROW
AROW
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
21.5%
-578.5%
Q1 24
26.8%
-789.9%
Capex Intensity
AROW
AROW
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
4.5%
8.2%
Q1 24
3.4%
48.2%
Cash Conversion
AROW
AROW
RXRX
RXRX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
1.06×
Q1 24
1.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons